RobertRichardFlavellMDPhD
Nuclear Medicine • New York, NYFellow, Nuclear Medicine, University of California, San Francisco
Dr. Flavell is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
505 Parnassus Ave
Box 0628
New York, NY 94143
Education & Training
University of California (San Francisco)Fellowship, Nuclear Medicine, 2016- University of California (San Francisco)Residency, Radiology-Diagnostic, 2011 - 2015
Memorial Sloan Kettering Cancer CenterInternship, Transitional Year, 2010 - 2011
Weill Cornell MedicineClass of 2010
Rockefeller UniversityPhD, Chemical Biology, 2004 - 2009
Certifications & Licensure
CA State Medical License 2011 - 2025- American Board of Nuclear Medicine Nuclear Medicine
- American Board of Radiology Diagnostic Radiology
Clinical Trials
- [18F]FAraG PET Imaging for Analysis of Biodistribution in Cancer Patients Expected to Undergo Immunotherapy and/or Radiation Therapy Start of enrollment: 2017 May 01
Roles: Contact, Principal Investigator
Publications & Presentations
PubMed
- Protocol for producing hyperpolarizedC-bicarbonate for clinical MRI of extracellular pH in aggressive tumors.Changhua Mu, Xiaoxi Liu, Andrew Riselli, James Slater, Evelyn Escobar
STAR Protocols. 2024-09-20 - Impact of Posttreatment SPECT/CT on Patient Management DuringLu-PSMA-617 Radiopharmaceutical Therapy.Surekha Yadav, Blair Lowery, Abuzar Moradi Tuchayi, Fei Jiang, Rachelle Saelee
Journal of Nuclear Medicine. 2024-09-03 - 1 citations3D small-scale dosimetry and tumor control ofAc radiopharmaceuticals for prostate cancer.Robin Peter, Anil P Bidkar, Kondapa Naidu Bobba, Luann Zerefa, Chandrashekhar Dasari
Scientific Reports. 2024-08-27
Journal Articles
- First-in-Human Phase I Study of CTT1057, a Novel 18F Labeled Imaging Agent with Phosphoramidate Core Targeting Prostate Specific Membrane Antigen in Prostate CancerSpencer C Behr, Hao G Nguyen, Thomas A Hope, Kirsten L Greene, Matthew R Cooperberg, Robert R Flavell, Eric J Small, Peter R Carroll, Journal of Nuclear Medicine
Press Mentions
Shuttle Enters Agreement with UCSF to Develop PSMA LigandDecember 19th, 2024
First-of-Its-Kind Study Demonstrates Clinical Impact of Amyloid PET ImagingApril 3rd, 2019- Conference Convenes Experts in the Field of Nuclear Medicine to Advance Prostate Cancer CareJanuary 26th, 2024
Grant Support
- Mitzi and William Blahd, MD Pilot Research GrantEducation and Research Foundation for Nuclear Medicine and Molecular Imaging2015–2016
- Research fellow grantRadiological Society of North America2015–2016
- T32NIH2014–2015
Committees
- Intern, Society of Nuclear Medicine, Clinical Trials Network 2015 - Present
Research History
- T32 Research Resident2014 - 2015
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
